This coupled with the fact that anti-B220 (which targets pre-mNKs) enhances melanoma rejection to a greater extent than anti-Asialo-GM1 (which targets NK cells, although slightly less effectively than anti-NK1.1) following ACT suggests that pre-mNK cells are regulating the activity of the adoptively transferred CD4+ T cells. The gene discussed is CD4; the disease is melanoma.